Resumen de Análisis de la utilización de medicamentos en los GRD 88 y 541: Enfermedad pulmonar obstructiva crónica (EPOC) y EPOC con reagudización
Usua Cilveti Sánchez, M. Arenere Mendoza, Mónica Izuel Rami, Elena Urbieta Sanz, Manuel Gómez Barrera
Objective: To know the drug use profiles and the associated cost of COPD and re-acute COPD treatment in the Pneumology and Internal Medicine. Method: Retrospective study of patients entered during the first three months of 2003, assigned with DRG 88 or 541 assigned. Results: The number of entrances has been 36 and 131, the average stay 11.0 and 12.6 days and the cost/stay 12.1 and 16.2 for the DRG 88 and 541, respectively. The most prescribed pharmacological groups in the DRG 88 have been J01 (83.3%) and the R03 (80.6%). In the DRG 541, J01 (88.6%) and H02 (84.9%). Those who have produced a higher cost both for the DRG 88 as well as for the 541 have been J01 (46.7% and 43.8%) and R03 (23.6% and 15.4%). The most prescribed antibiotics were for DRG 88 and 541 the penicillins plus the beta-lactamase inhibitors (47.2%; 50.0%). The most prescribed inhalers were ß-2 adrenergics in DRG 88 (75.0%) and anticholinergics in DRG 541 (81.1%). Proton-pump inhibitors (PPIs) were used in 69.4% of patients from the DRG 88 and in 62.8% of those from the DRG 541. 67.4% of patients in DRG 541 were treated with low-molecular-weight heparins (LMWHs) and 38.9% in the DRG 88. Conclusions: 1. The treatment profiles of DRGs 88 and 541 coincide with the recommendations from clinical guidelines and published data. 2. There is a high level of prescription of fluorquinolones. 3. The results confirm the most used active principles according to the EPIMED 2001 study
